NCT01202409View on ClinicalTrials.gov

CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater

PHASE2CompletedINTERVENTIONAL

Enrollment

19

Participants

Timeline

Start Date

November 2, 2010

Primary Completion Date

July 3, 2018

Study Completion Date

July 3, 2018

Conditions

Gastrointestinal Cancer

Interventions

DRUG

Panitumumab

Starting Dose Level: 9 mg/kg by vein over 60 minutes on day 1 of a 14 day cycle.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Amgen

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER